ctps1 Antibody

What is CTPS1 and why is it important in cellular research?

CTPS1 is a 591 amino acid enzyme that plays a critical role in pyrimidine metabolism, specifically catalyzing the ATP-dependent conversion of uridine triphosphate (UTP) to cytidine triphosphate (CTP). This reaction represents a rate-limiting step in nucleic acid synthesis, making CTPS1 essential for proper cell growth and development . The enzyme is primarily located in the cytoplasm, where it facilitates the availability of CTP, a crucial building block for RNA synthesis and cellular energy metabolism.

The importance of CTPS1 extends beyond basic metabolic functions. Its regulation involves complex post-translational modifications, including phosphorylation by protein kinase C, which can modulate its activity and influence cellular responses to growth signals . The gene encoding CTPS1 is situated on chromosome 1, a region frequently implicated in the progression of several cancers, highlighting its potential involvement in tumorigenesis.

Recent research has identified CTPS1 as a novel therapeutic target in B- and T-cell cancers, further elevating interest in studying this enzyme and its functions . As a key player in fundamental cellular processes and a potential therapeutic target, CTPS1 represents an important focus for researchers across multiple disciplines.

What types of CTPS1 antibodies are available for research purposes?

Several types of CTPS1 antibodies are available for research applications, each with specific characteristics suitable for different experimental approaches. The two primary categories include:

Monoclonal antibodies: These offer high specificity and consistency between batches. For example, the CTPS1 Antibody (2G7-1D10) is a mouse monoclonal IgG2b kappa light chain antibody that detects CTPS1 protein of mouse, rat, and human origin . This antibody is validated for western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA) applications.

Polyclonal antibodies: These recognize multiple epitopes and often provide stronger signals. The CTPS1 Rabbit Polyclonal Antibody (CAB3817) is produced in rabbits and shows high reactivity with human and mouse samples . This antibody was developed using a recombinant fusion protein containing a sequence corresponding to amino acids 402-591 of human CTPS1 (NP_001896.2).

When selecting a CTPS1 antibody, researchers should consider the following factors:

• Species reactivity required (human, mouse, rat)

• Intended applications (WB, IP, ELISA, etc.)

• Isotype preferences

• Recognition region within the CTPS1 protein

• Validation data available for the specific experimental context

These considerations will ensure selection of the appropriate antibody tool for investigating CTPS1 in various research contexts.

What are the recommended experimental conditions for using CTPS1 antibodies in Western blot applications?

For optimal results when using CTPS1 antibodies in Western blot applications, researchers should follow these methodological guidelines:

Dilution range: The recommended dilution for CTPS1 antibodies varies by product. For instance, the CTPS1 Rabbit Polyclonal Antibody (CAB3817) has a recommended dilution range of 1:500 to 1:2000 for Western blot applications . Always perform an antibody titration experiment to determine the optimal concentration for your specific sample type and detection system.

Sample preparation: When preparing cell or tissue lysates, use a lysis buffer containing protease inhibitors to prevent CTPS1 degradation. Since CTPS1 is primarily located in the cytoplasm, cytoplasmic extraction protocols may be particularly effective.

Gel percentage: As CTPS1 is a 591 amino acid protein with a molecular weight of approximately 67 kDa, 8-10% SDS-PAGE gels typically provide good resolution.

Blocking conditions: Use 5% non-fat dry milk or 3-5% BSA in TBST (Tris-buffered saline with 0.1% Tween-20) for blocking, with an incubation time of 1 hour at room temperature.

Primary antibody incubation: Incubate membranes with diluted primary CTPS1 antibody overnight at 4°C with gentle agitation to ensure consistent binding while minimizing background.

Controls: Include appropriate positive controls (cell lines known to express CTPS1, such as JURKAT cells) and negative controls (CTPS1 knockout cells, if available) to validate antibody specificity.

Detection method: Both chemiluminescent and fluorescent secondary detection systems are compatible with CTPS1 antibodies, though fluorescent systems may offer better quantification potential.

Following these guidelines will help ensure consistent and reliable detection of CTPS1 protein in Western blot experiments, enabling accurate analysis of CTPS1 expression levels across different experimental conditions.

How can CTPS1 antibodies be utilized in investigating the efficacy of CTPS1 inhibitors as potential therapeutics?

CTPS1 antibodies serve as essential tools for evaluating the efficacy and mechanism of action of CTPS1 inhibitors in preclinical research. Recent studies have identified CTPS1 as a novel therapeutic target in lymphoma, with selective small molecule inhibitors showing promising results . Researchers can employ several methodological approaches using CTPS1 antibodies:

Target engagement assays: Researchers can use CTPS1 antibodies in cellular thermal shift assays (CETSA) to confirm binding of inhibitors to CTPS1 in intact cells. This technique helps distinguish between direct CTPS1 inhibition and off-target effects.

Inhibitor specificity validation: Western blot analysis with CTPS1 and CTPS2 antibodies can help evaluate the isoform specificity of inhibitors. As demonstrated in recent research, compounds like STP-A and STP-B show differential inhibitory effects on CTPS1 versus CTPS2, with selectivity influenced by specific amino acid residues such as isoleucine 250 .

Pharmacodynamic biomarker development: CTPS1 antibodies can be employed to measure changes in CTPS1 protein levels or post-translational modifications following inhibitor treatment, potentially serving as pharmacodynamic biomarkers for clinical development.

Mechanism of action studies: Combining CTPS1 antibodies with apoptosis markers can help elucidate whether CTPS1 inhibitors induce cell death through apoptotic pathways, as has been observed in lymphoid cell lines . Western blot analysis of downstream pathways can further characterize the cellular response to CTPS1 inhibition.

Resistance mechanism investigation: In models developing resistance to CTPS1 inhibitors, antibodies can help identify alterations in CTPS1 expression, localization, or post-translational modifications that might contribute to the resistant phenotype.

Recent research has demonstrated that selective CTPS1 inhibitors (e.g., STP-A and STP-B) block the in vitro proliferation of human neoplastic cells, with highest potency against lymphoid neoplasms . These studies highlight the potential of CTPS1 as a therapeutic target and underscore the value of CTPS1 antibodies in advancing this promising area of investigation.

What approaches can be used to investigate differences between CTPS1 and CTPS2 isoforms using antibody-based methods?

Distinguishing between CTPS1 and CTPS2 isoforms is crucial for understanding their differential roles in normal physiology and disease. Several antibody-based approaches can be employed:

Isoform-specific Western blotting: Using antibodies that specifically recognize unique epitopes in either CTPS1 or CTPS2 allows direct comparison of expression levels. When selecting antibodies, researchers should verify specificity through genetic validation (e.g., testing in CTPS1 or CTPS2 knockout cells). The complementation assay systems described in recent literature, where JURKAT cells lacking endogenous CTPS1 are used, provide excellent controls for antibody specificity .

Co-immunoprecipitation studies: Isoform-specific antibodies can be used to investigate whether CTPS1 and CTPS2 interact with different binding partners. This approach can reveal distinct signaling pathways or regulatory mechanisms affecting each isoform.

Immunofluorescence microscopy: Dual staining with isoform-specific antibodies can reveal differential subcellular localization of CTPS1 and CTPS2, particularly under various cellular stresses or following treatment with inhibitors.

ChIP-seq analysis: For investigating transcriptional regulation, chromatin immunoprecipitation followed by sequencing can identify distinct transcription factors controlling CTPS1 versus CTPS2 expression.

Proximity ligation assays: These can detect and quantify protein-protein interactions specific to each isoform in situ, potentially revealing functional differences in protein complex formation.

Research has identified key structural differences between CTPS1 and CTPS2 that affect inhibitor binding, particularly the isoleucine 250 residue in CTPS1 (corresponding to threonine 250 in CTPS2) . Mutation studies where CTPS1-I250T showed reduced sensitivity to inhibitors like STP-A, while CTPS2-T250I gained sensitivity, highlight the importance of this residue. Antibody-based approaches can be complemented with these genetic studies to develop a comprehensive understanding of isoform-specific functions and inhibitor responses.

How can CTPS1 antibodies be used in conjunction with CRISPR-based gene editing for functional studies?

CTPS1 antibodies serve as valuable tools in CRISPR-based gene editing experiments, enabling comprehensive validation and functional characterization of genetic modifications. Several methodological approaches integrate antibody detection with gene editing techniques:

Knockout validation: Western blotting with CTPS1 antibodies provides essential confirmation of successful CTPS1 gene knockout. Recent studies have utilized CRISPR to generate CTPS1-null JURKAT cells, with knockout validation performed through Western blotting . This approach confirms complete protein loss rather than simply frameshift mutations that might result in truncated but potentially functional protein products.

Rescue experiments: After CTPS1 knockout, researchers can reintroduce wild-type or mutant CTPS1 variants and use antibodies to verify expression levels. This approach has been employed in complementation assays where CTPS1-null cells were reconstituted with various CTPS1 or CTPS2 constructs to study the role of specific amino acid residues in inhibitor sensitivity .

Domain function analysis: CRISPR-based precise editing of specific CTPS1 domains (e.g., ATP binding pocket, catalytic domain) combined with antibody detection can reveal the importance of these regions for protein stability, localization, and function.

Identifying compensatory mechanisms: In CTPS1 knockout models, antibodies against CTPS2 can help determine whether compensatory upregulation occurs, providing insights into functional redundancy between isoforms.

Investigating synthetic lethality: CTPS1 antibodies can assist in validating combination CRISPR screens aimed at identifying genes that, when co-targeted with CTPS1, produce synthetic lethality in cancer cells.

When designing CRISPR-based CTPS1 studies, it's important to note that complete CTPS1 knockout may affect cell viability, particularly in cell types highly dependent on de novo pyrimidine synthesis. Research has shown that JURKAT cells lacking CTPS1 require supraphysiological concentrations of cytidine (200 μM) in the culture medium to maintain viability through the salvage pathway . This observation highlights the essential nature of CTPS1 in certain cellular contexts and underscores the importance of carefully designed controls in CRISPR-based functional studies.

What is the significance of CTPS1 as a therapeutic target in lymphoid malignancies?

CTPS1 has emerged as a promising therapeutic target in lymphoid malignancies, with several lines of evidence supporting its clinical relevance. Recent research has identified and characterized CTPS1 as a novel target specifically in B- and T-cell cancers .

The therapeutic potential of CTPS1 inhibition in lymphoid malignancies is supported by several key findings:

Selective cytotoxicity: Pharmacological CTPS1 inhibition has demonstrated potent anti-proliferative effects in human neoplastic cells, with highest potency observed against lymphoid neoplasms . Importantly, CTPS1 inhibition induces cell death by apoptosis in the majority of lymphoid cell lines tested, indicating a cytotoxic rather than cytostatic mechanism of action. This selective effect suggests a potential therapeutic window between malignant and normal cells.

In vivo efficacy: Selective CTPS1 inhibition has been shown to inhibit the growth of neoplastic human B- and T-cells in vivo, providing preclinical proof-of-concept for therapeutic development . These findings suggest that CTPS1 inhibitors could potentially translate into clinical efficacy.

Targeted approach: The JURKAT cell line, derived from a patient with T-cell acute lymphoblastic leukemia, expresses CTPS1 but not CTPS2 due to a hemizygous deletion of the CTPS2 gene on the X chromosome . This observation suggests that some lymphoid malignancies may be particularly dependent on CTPS1, making them especially vulnerable to CTPS1 inhibition.

Small molecule development: A series of potent and highly selective small molecule inhibitors of CTPS1 have been developed, with site-directed mutagenesis studies identifying the adenosine triphosphate pocket of CTPS1 as the binding site . These compounds demonstrate the feasibility of developing specific CTPS1-targeted agents.

CTPS1 antibodies play a crucial role in advancing this therapeutic approach by enabling the characterization of CTPS1 expression in patient samples, evaluation of inhibitor effects on CTPS1 in preclinical models, and potentially serving as companion diagnostics to identify patients most likely to benefit from CTPS1-targeted therapy. The continuing development of specific CTPS1 inhibitors, guided by antibody-based research, holds promise for novel treatment strategies in lymphoid malignancies.

How can CTPS1 antibodies be utilized for biomarker development in cancer research?

CTPS1 antibodies offer significant potential for biomarker development in cancer research, potentially informing diagnosis, prognosis, and treatment selection. Several methodological approaches can be employed:

Expression profiling in tissue microarrays: CTPS1 antibodies can be used in immunohistochemistry (IHC) studies of tissue microarrays comprising various cancer types and normal tissues. This approach helps establish baseline expression patterns and identify cancer types with abnormal CTPS1 expression. Particular attention should be given to lymphoid malignancies, where CTPS1 has shown therapeutic relevance .

Liquid biopsy development: CTPS1 antibodies can be adapted for the detection of circulating tumor cells (CTCs) or exosomes, potentially enabling liquid biopsy approaches for monitoring treatment response or disease recurrence.

Predictive biomarker for CTPS1 inhibitors: As CTPS1 inhibitors advance toward clinical development, antibody-based assessment of CTPS1 expression, localization, or post-translational modifications could help identify patients most likely to respond to these targeted therapies.

Multiplexed immunofluorescence: Combining CTPS1 antibodies with markers of cell proliferation, apoptosis, or lineage-specific antigens in multiplexed immunofluorescence can provide insights into the biological context of CTPS1 expression and its functional implications.

When developing CTPS1 as a biomarker, researchers should consider potential confounding factors such as the influence of the cell cycle on CTPS1 expression, the presence of CTPS2 which may compensate for CTPS1 deficiency, and the potential impact of post-translational modifications on antibody recognition. Rigorous validation using multiple antibodies and complementary techniques (e.g., RNA-seq, proteomics) is essential for establishing CTPS1 as a reliable biomarker in cancer research.

What considerations are important when using CTPS1 antibodies to evaluate patient samples in clinical research?

When utilizing CTPS1 antibodies for clinical research involving patient samples, several critical considerations must be addressed to ensure reliable and reproducible results:

Antibody validation for clinical specimens: Before applying CTPS1 antibodies to valuable patient samples, rigorous validation should be performed using appropriate positive controls (cell lines with known CTPS1 expression levels) and negative controls (CTPS1 knockout cells or tissues). Special attention should be paid to validating antibodies specifically for fixed tissue applications, as epitope accessibility may differ from that in cell lysates used for Western blots.

Standardized protocols: Development and adherence to standardized immunohistochemistry or immunofluorescence protocols is essential for comparing CTPS1 expression across patient cohorts. This includes consistent fixation methods, antigen retrieval conditions, antibody concentrations, incubation times, and detection systems.

Quantification methods: Establishing reliable quantification methods for CTPS1 expression in tissue samples is crucial. Digital pathology approaches using image analysis software can provide objective quantification, reducing inter-observer variability. Clear criteria should be established for what constitutes "high" versus "low" CTPS1 expression.

Sample heterogeneity: Cancer tissues often display heterogeneous expression patterns. Multiple regions of each sample should be evaluated, and heterogeneity should be documented and considered in data interpretation.

Correlation with molecular data: When possible, CTPS1 immunostaining results should be correlated with molecular data such as RNA-seq or proteomic profiling to provide a more comprehensive understanding of CTPS1 biology in patient samples.

Ethical considerations: Proper informed consent and institutional review board approval must be obtained for the use of patient samples in CTPS1 research. Patient privacy and data protection regulations must be strictly followed.

By addressing these considerations systematically, researchers can maximize the translational value of CTPS1 antibody-based studies in clinical specimens, potentially advancing both basic understanding of CTPS1 biology in human disease and the development of CTPS1-targeted therapeutic approaches.

What are the key considerations for validating CTPS1 antibody specificity in experimental systems?

Thorough validation of CTPS1 antibody specificity is essential for generating reliable and reproducible research data. Researchers should implement a multi-faceted validation strategy:

Genetic approaches: The gold standard for antibody validation involves testing in systems with genetic manipulation of the target protein. For CTPS1 antibodies, this includes:

• Testing in CTPS1 knockout cells, such as the JURKAT CTPS1-null cells described in recent literature

• Comparing expression in cells with CTPS1 overexpression versus control cells

• Using siRNA knockdown as an alternative approach when knockout models are unavailable

Cross-reactivity assessment: Given the sequence similarity between CTPS1 and CTPS2 (approximately 74% identity), evaluating potential cross-reactivity is crucial:

• Compare antibody reactivity in cells expressing only CTPS1 (e.g., JURKAT cells with CTPS2 deletion) versus cells expressing only CTPS2 (e.g., CTPS1 knockout cells complemented with CTPS2)

• Test antibody recognition of recombinant CTPS1 versus CTPS2 proteins in controlled systems

Epitope mapping: Understanding the specific region of CTPS1 recognized by the antibody helps predict potential cross-reactivity and interpret results:

• For polyclonal antibodies like CAB3817, knowledge that it was generated against amino acids 402-591 of human CTPS1 helps predict specificity

• Peptide competition assays using the immunogen peptide can confirm epitope specificity

Multiple antibody concordance: Using multiple antibodies targeting different epitopes of CTPS1 and comparing their detection patterns provides additional validation:

• Concordant results with antibodies from different host species or different vendors increases confidence

• Discordant results should prompt further investigation to determine which antibody is more specific

Orthogonal methods: Correlating antibody-based detection with orthogonal methods provides comprehensive validation:

• Compare protein detection with mRNA expression (RT-qPCR, RNA-seq)

• Correlation with functional assays of CTPS1 activity

By implementing these validation approaches systematically, researchers can establish confidence in CTPS1 antibody specificity, ensuring that experimental observations truly reflect CTPS1 biology rather than artifacts of non-specific antibody binding.

What methods can be used to investigate post-translational modifications of CTPS1 using antibody-based approaches?

Post-translational modifications (PTMs) play crucial roles in regulating CTPS1 function, particularly through phosphorylation by protein kinase C . Investigating these modifications requires specialized antibody-based approaches:

Phospho-specific antibodies: For studying CTPS1 phosphorylation:

• Phospho-specific antibodies targeting known or predicted phosphorylation sites can be used in Western blot analysis before and after treatments that activate relevant kinases

• When commercial phospho-specific antibodies are unavailable, custom antibodies can be generated against synthetic phosphopeptides corresponding to key regulatory sites

• Validation of phospho-antibodies should include treatment with phosphatase to confirm specificity for the phosphorylated form

Immunoprecipitation followed by mass spectrometry (IP-MS):

• CTPS1 can be immunoprecipitated using validated antibodies, followed by mass spectrometry analysis to identify and quantify multiple PTMs simultaneously

• This approach is particularly valuable for discovering novel modifications and generating comprehensive PTM profiles

• SILAC (Stable Isotope Labeling with Amino acids in Cell culture) can be incorporated to quantitatively compare PTM changes across different conditions

Proximity ligation assay (PLA):

• PLA combines antibodies against CTPS1 and specific modifying enzymes (e.g., kinases, acetylases) to detect their proximity in situ

• This technique allows visualization of potential enzyme-substrate interactions in their native cellular context

• Multiple PLAs can be performed to investigate different modification pathways simultaneously

2D gel electrophoresis with Western blot:

• CTPS1 isoforms with different modifications can be separated based on both molecular weight and isoelectric point

• Subsequent Western blotting with CTPS1 antibodies can reveal the presence of multiple modified forms

• Comparison before and after treatments affecting PTMs can reveal dynamic regulation

Protein microarray approaches:

• Arrays spotted with CTPS1 antibodies can be used to capture the protein from cell lysates

• Subsequent probing with modification-specific antibodies allows high-throughput analysis of multiple modifications

When investigating CTPS1 PTMs, researchers should consider that modifications may affect antibody recognition, potentially leading to false-negative results. Additionally, the stoichiometry of modifications is often low, requiring sensitive detection methods and appropriate enrichment strategies. Understanding CTPS1's complex regulation through PTMs may provide insights into its role in normal cellular function and disease states, potentially revealing new therapeutic opportunities.

How does CTPS1 contribute to the metabolic reprogramming observed in cancer cells?

CTPS1's role in cancer metabolic reprogramming represents an exciting frontier in cancer research. As a rate-limiting enzyme in the de novo pyrimidine synthesis pathway, CTPS1 is positioned at a critical intersection of cellular metabolism and proliferation:

Nucleotide metabolism and proliferation: Cancer cells typically exhibit accelerated proliferation requiring enhanced nucleotide synthesis. CTPS1 catalyzes the conversion of UTP to CTP, a rate-limiting step in pyrimidine synthesis . This makes CTPS1 potentially critical for sustaining the high replication rates characteristic of malignant cells. Researchers can investigate this connection by:

• Correlating CTPS1 expression with proliferation markers in cancer tissues

• Measuring nucleotide pools before and after CTPS1 inhibition

• Examining cell cycle profiles in models with modified CTPS1 expression

Integration with other metabolic pathways: CTPS1 function intersects with broader metabolic networks including:

• Glutamine metabolism (glutamine provides nitrogen for the amination reaction)

• Energy metabolism (ATP is required for CTP synthesis)

• Lipid metabolism (CTP is required for phospholipid synthesis)

Antibody-based co-localization studies with markers of these pathways can reveal spatial relationships within the cell, while proteomic approaches can identify physical interactions between CTPS1 and other metabolic enzymes.

Regulatory signaling: CTPS1 is regulated by protein kinase C through phosphorylation , potentially linking it to growth factor signaling pathways frequently dysregulated in cancer. Phospho-specific antibodies against CTPS1 can help elucidate how oncogenic signaling cascades might influence CTPS1 activity and subsequent metabolic reprogramming.

Therapeutic implications: The observation that CTPS1 inhibition shows highest potency against lymphoid neoplasms suggests particular dependence of these cancers on CTPS1-mediated metabolism. This differential sensitivity warrants investigation into the metabolic vulnerabilities unique to different cancer types, potentially revealing new therapeutic strategies.

Research into CTPS1's role in cancer metabolism could be advanced through metabolic flux analysis combined with antibody-based assessment of CTPS1 expression and localization. Such studies might reveal whether CTPS1 represents a critical node in cancer metabolic networks that could be targeted therapeutically, particularly in malignancies showing heightened dependence on de novo pyrimidine synthesis.

What is the relationship between CTPS1 and immune cell function, and how can this be studied using antibody-based approaches?

The relationship between CTPS1 and immune cell function represents an emerging area of research with potential implications for both immunology and cancer immunotherapy. CTPS1's role in immune cells can be investigated through various antibody-based approaches:

Expression profiling across immune cell subtypes: Using CTPS1 antibodies for immunohistochemistry or flow cytometry analysis of different immune cell populations can reveal differential expression patterns. This approach can identify which immune cell types most heavily rely on CTPS1-mediated pyrimidine synthesis, potentially explaining the particular sensitivity of lymphoid neoplasms to CTPS1 inhibition .

Immune synapse localization: Advanced microscopy techniques combined with CTPS1 antibodies can investigate whether CTPS1 localizes to specific subcellular regions during immune cell activation, such as the immunological synapse in T cells. Such localization might suggest specialized metabolic regulation during immune effector functions.

Impact on cytokine production: After CTPS1 inhibition or genetic manipulation, antibody-based methods like intracellular cytokine staining or cytokine secretion assays can assess effects on immune cell effector functions. This approach helps distinguish between effects on proliferation versus functional activity.

Relationship with metabolic checkpoints: Multiplexed immunofluorescence combining CTPS1 antibodies with markers of metabolic pathways (e.g., mTOR signaling, AMPK activation) can reveal how CTPS1 integrates with established metabolic checkpoints known to regulate immune cell function.

In vivo immune responses: Immunohistochemistry using CTPS1 antibodies in tissues from animal models undergoing immune challenges can assess the role of CTPS1 in physiological immune responses. This approach provides context beyond isolated cell studies.

The relationship between CTPS1 and immune function has particular relevance for therapeutic development. If CTPS1 inhibitors primarily affect rapidly proliferating immune cells, potential immunosuppressive effects would need careful evaluation during drug development. Conversely, if CTPS1 inhibition specifically targets dysfunctional immune responses in certain contexts, this could present opportunities for immunomodulatory therapies beyond direct anti-cancer applications.